Stock listing

Pharvaris N.v.

Selected listing: A2QNWS · LS · EUR · DE

Pharvaris N.v. (Lang & Schwarz: A2QNWS), Health Technology. Latest release Oct 5, 2026: Real-World Analysis Highlighting HAE Disease Experience and Gaps…

A2QNWS:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2QNWS
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Pharvaris N.v.

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

October 5, 2026

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

September 8, 2026

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

September 3, 2026

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

July 22, 2026

All Pharvaris N.v. news →

Research Pharvaris N.v.

Pharvaris N.v. company profile

View the public company page for Pharvaris N.v. on 6ix.

Pharvaris N.v. news

Read company news and market updates connected to Pharvaris N.v..

Pharvaris N.v. investor events

Find investor webinars, events, and replay context for Pharvaris N.v..